Breaking News Instant updates and real-time market news.

GKOS

Glaukos

$59.51

14.72 (32.86%)

, NVS

Novartis

$83.75

-0.03 (-0.04%)

12:02
08/29/18
08/29
12:02
08/29/18
12:02

JPMorgan upgrades Glaukos after 'main competitor' pulls product

As previously reported, JPMorgan analyst Robert Marcus upgraded Glaukos (GKOS) to Overweight from Neutral, calling Alcon's (NVS) voluntary withdrawal of its micro-stent from the market a "significant win" that opens up an opportunity for Glaukos to take back principally all of the sales being generated by CyPass. Stating that he's always been a firm believer in Glaukos' pipeline and technology, Marcus said competition had been the main factor keeping him on the sidelines. Now that its "main competitor" is out of the way, he sees Glaukos having a meaningful opportunity to recapture share and lead the market. Marcus raised his price target on the stock to $75 from $42.

GKOS

Glaukos

$59.51

14.72 (32.86%)

NVS

Novartis

$83.75

-0.03 (-0.04%)

  • 05

    Sep

  • 12

    Sep

GKOS Glaukos
$59.51

14.72 (32.86%)

08/29/18
PIPR
08/29/18
NO CHANGE
Target $55
PIPR
Overweight
Piper sees CyPass withdrawal as 'major boon' for Glaukos, ups target to $55
Piper Jaffray analyst Matt O'Brien views Alcon's immediate withdrawal of its CyPass stent for the treatment of glaucoma on safety concerns from a recently completed clinical study as a "major boon" for Glaukos (GKOS). The analyst suspects it will be several quarters before CyPass comes back to the market, with with a much narrower indication. This is a "major positive" for Glaukos as most of the clinicians using CyPass had been or are still using iStent from Glaukos, O'Brien tells investors in a research note. He anticipates many clinicians will quickly shift their volumes back to iSten, yielding "significant incremental revenues." Based on this morning's news, the analyst raised his price target for Glaukos shares to $55 from $46. He encourages investors to start or build positions in the name.
08/29/18
SPHN
08/29/18
NO CHANGE
Target $57
SPHN
Overweight
Glaukos price target raised to $57 at Stephens after Novartis withdraws CyPass
Stephens analyst Chris Cooley raised his price target on Glaukos (GKOS) shares to $57 from $50 after Novartis' (NVS) Alcon unit withdrew the CyPass micro-stent from the market due to safety concerns. He estimates $40M-$50M in annual sales are now "in play" and see Glaukos as the most likely beneficiary, Cooley tells investors. He maintains an Overweight rating on Glaukos shares, which are up $17.35, or 39%, to $62.15 in pre-market trading.
08/29/18
JPMS
08/29/18
UPGRADE
JPMS
Overweight
Glaukos upgraded to Overweight from Neutral at JPMorgan
NVS Novartis
$83.75

-0.03 (-0.04%)

08/29/18
WBLR
08/29/18
NO CHANGE
WBLR
Outperform
CyPass market removal a 'clear positive' for Glaukos, says William Blair
William Blair analyst Brian Weinstein believes Alcon's voluntary global market withdrawal of its CyPass Micro-Stent for surgical glaucoma is a "clear positive for near-term numbers" at Glaukos (GKOS). If Glaukos' iStent takes all of the CyPass market share while it is off the market, the company could add as much as $50M in the U.S. alone to its 2019 total revenue of around $186M, Weinstein tells investors in a research note, while admitting this is a bullish stance. The analyst thinks the news this morning from Alcon should be viewed as a positive for Glaukos, as a major part of the short thesis was on competition in the core iStent market, mainly from Alcon. He keeps an Outperform rating on Glaukos shares.

TODAY'S FREE FLY STORIES

RNSDF

Renault

$0.00

(0.00%)

, NSANY

Nissan

$0.00

(0.00%)

06:36
12/12/18
12/12
06:36
12/12/18
06:36
Periodicals
Renault tells Nissan to stop contacting board members, Reuters reports »

Renault (RNSDF) has told…

RNSDF

Renault

$0.00

(0.00%)

NSANY

Nissan

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

UIS

Unisys

$12.72

-0.32 (-2.45%)

06:36
12/12/18
12/12
06:36
12/12/18
06:36
Recommendations
Unisys analyst commentary  »

Unisys price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACIU

AC Immune

$11.58

0.63 (5.75%)

, LLY

Eli Lilly

$114.49

0.38 (0.33%)

06:32
12/12/18
12/12
06:32
12/12/18
06:32
Hot Stocks
AC Immune, Eli Lilly announce license and collaboration agreement »

AC Immune (ACIU) and Eli…

ACIU

AC Immune

$11.58

0.63 (5.75%)

LLY

Eli Lilly

$114.49

0.38 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

OMI

Owens & Minor

$7.11

-0.19 (-2.60%)

06:32
12/12/18
12/12
06:32
12/12/18
06:32
Hot Stocks
Owens & Minor names Robert Snead as EVP & CFO »

Owens & Minor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BKH

Black Hills

$67.28

0.06 (0.09%)

06:31
12/12/18
12/12
06:31
12/12/18
06:31
Downgrade
Black Hills rating change  »

Black Hills downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMR

Emerson

$62.30

-0.28 (-0.45%)

06:30
12/12/18
12/12
06:30
12/12/18
06:30
Downgrade
Emerson rating change  »

Emerson downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ES

Eversource

$70.18

0.53 (0.76%)

06:30
12/12/18
12/12
06:30
12/12/18
06:30
Downgrade
Eversource rating change  »

Eversource downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

GOOG

Alphabet

$1,051.82

11.8 (1.13%)

, GOOGL

Alphabet Class A

$1,061.32

8.52 (0.81%)

06:29
12/12/18
12/12
06:29
12/12/18
06:29
Periodicals
Google CEO faces questions from lawmakers on alleged political bias, WSJ says »

Google CEO Sundar Pichai…

GOOG

Alphabet

$1,051.82

11.8 (1.13%)

GOOGL

Alphabet Class A

$1,061.32

8.52 (0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

CS

Credit Suisse

$10.92

-0.09 (-0.82%)

06:27
12/12/18
12/12
06:27
12/12/18
06:27
Hot Stocks
Credit Suisse sees FY18 reported pre-tax income CHF3.2B-CHF3.4B »

Sees FY18 APAC Markets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CS

Credit Suisse

$10.92

-0.09 (-0.82%)

06:25
12/12/18
12/12
06:25
12/12/18
06:25
Hot Stocks
Credit Suisse board approves buyback of up to CHF1.5B »

At its 2018 investor day,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAR

Marriott

$110.04

-0.78 (-0.70%)

06:22
12/12/18
12/12
06:22
12/12/18
06:22
Periodicals
Chinese hackers behind Marriott data breach, NY Times reports »

The cyberattack on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIX

Six Flags

$58.40

-1.46 (-2.44%)

06:20
12/12/18
12/12
06:20
12/12/18
06:20
Initiation
Six Flags initiated  »

Six Flags initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,051.82

11.8 (1.13%)

, GOOGL

Alphabet Class A

$1,061.32

8.52 (0.81%)

06:20
12/12/18
12/12
06:20
12/12/18
06:20
Periodicals
Snowden, others call for Pichai to kill Google's 'Project Dragonfly,' BI reports »

NSA whistleblower Edward…

GOOG

Alphabet

$1,051.82

11.8 (1.13%)

GOOGL

Alphabet Class A

$1,061.32

8.52 (0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

BY

Byline Bancorp

$18.91

-0.32 (-1.66%)

06:18
12/12/18
12/12
06:18
12/12/18
06:18
Conference/Events
Byline Bancorp management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

RY

Royal Bank of Canada

$69.76

-0.44 (-0.63%)

06:17
12/12/18
12/12
06:17
12/12/18
06:17
Upgrade
Royal Bank of Canada rating change  »

Royal Bank of Canada…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

CORT

Corcept Therapeutics

$17.16

4.18 (32.20%)

06:17
12/12/18
12/12
06:17
12/12/18
06:17
Upgrade
Corcept Therapeutics rating change  »

Corcept Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LULU

Lululemon

$116.67

1.66 (1.44%)

06:17
12/12/18
12/12
06:17
12/12/18
06:17
Upgrade
Lululemon rating change  »

Lululemon upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

BBY

Best Buy

, AMZN

Amazon.com

$1,643.50

3.13 (0.19%)

06:16
12/12/18
12/12
06:16
12/12/18
06:16
Recommendations
Best Buy, Amazon.com analyst commentary  »

Best Buy…

BBY

Best Buy

AMZN

Amazon.com

$1,643.50

3.13 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

  • 20

    Dec

KRYS

Krystal Biotech

$23.49

0.38 (1.64%)

06:16
12/12/18
12/12
06:16
12/12/18
06:16
Initiation
Krystal Biotech initiated  »

Krystal Biotech initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOMX

Foamix

$3.81

-0.19 (-4.75%)

06:13
12/12/18
12/12
06:13
12/12/18
06:13
Initiation
Foamix initiated  »

Foamix initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

, RNSDF

Renault

$0.00

(0.00%)

06:13
12/12/18
12/12
06:13
12/12/18
06:13
Periodicals
Nissan shares detailed allegations against Ghosn with Renault, FT reports »

Nissan (NSANY) has shared…

NSANY

Nissan

$0.00

(0.00%)

RNSDF

Renault

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

BHC

Bausch Health

$23.09

0.25 (1.09%)

, SGYP

Synergy Pharmaceuticals

$0.34

-0.0094 (-2.69%)

06:13
12/12/18
12/12
06:13
12/12/18
06:13
Hot Stocks
Bausch Health to acquire Synergy Pharmaceuticals for $200M through Chapter 11 »

Synergy Pharmaceuticals…

BHC

Bausch Health

$23.09

0.25 (1.09%)

SGYP

Synergy Pharmaceuticals

$0.34

-0.0094 (-2.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 25

    Feb

EADSY

Airbus

$0.00

(0.00%)

06:11
12/12/18
12/12
06:11
12/12/18
06:11
Periodicals
Airbus staff error led to fatal 2017 German helicopter crash, Reuters reports »

The fatal crash in 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEY

KeyCorp

$15.93

-0.075 (-0.47%)

06:09
12/12/18
12/12
06:09
12/12/18
06:09
Downgrade
KeyCorp rating change  »

KeyCorp downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$264.13

0.04 (0.02%)

06:07
12/12/18
12/12
06:07
12/12/18
06:07
Periodicals
Senate confirms Muzinich as Deputy Treasury Secretary, WSJ reports »

The Senate has confirmed…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$264.13

0.04 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.